712 related articles for article (PubMed ID: 15363980)
1. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
2. Continuous opioid agonist treatment dose-dependently regulates mu-opioid receptors and dynamin-2 in mouse spinal cord.
Zhang Q; Purohit V; Yoburn BC
Synapse; 2005 Jun; 56(3):123-8. PubMed ID: 15765525
[TBL] [Abstract][Full Text] [Related]
3. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
[TBL] [Abstract][Full Text] [Related]
4. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo.
Yoburn BC; Gomes BA; Rajashekara V; Patel C; Patel M
Synapse; 2003 Feb; 47(2):109-16. PubMed ID: 12454948
[TBL] [Abstract][Full Text] [Related]
5. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.
Shen J; Benedict Gomes A; Gallagher A; Stafford K; Yoburn BC
Synapse; 2000 Dec; 38(3):322-7. PubMed ID: 11020235
[TBL] [Abstract][Full Text] [Related]
6. In vivo regulation of mu-opioid receptor density and gene expression in CXBK and outbred Swiss Webster mice.
Duttaroy A; Yoburn BC
Synapse; 2000 Aug; 37(2):118-24. PubMed ID: 10881033
[TBL] [Abstract][Full Text] [Related]
7. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
8. mu-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to mu-opioid receptor agonists: Comparison between etorphine and morphine.
Narita M; Suzuki M; Narita M; Niikura K; Nakamura A; Miyatake M; Yajima Y; Suzuki T
Neuroscience; 2006; 138(2):609-19. PubMed ID: 16417975
[TBL] [Abstract][Full Text] [Related]
9. Opioid receptor regulation in mice.
Yoburn BC; Billings B; Duttaroy A
J Pharmacol Exp Ther; 1993 Apr; 265(1):314-20. PubMed ID: 8386239
[TBL] [Abstract][Full Text] [Related]
10. Chronic opioid antagonist treatment selectively regulates trafficking and signaling proteins in mouse spinal cord.
Patel CN; Rajashekara V; Patel K; Purohit V; Yoburn BC
Synapse; 2003 Oct; 50(1):67-76. PubMed ID: 12872295
[TBL] [Abstract][Full Text] [Related]
11. Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo.
Patel MB; Patel CN; Rajashekara V; Yoburn BC
Mol Pharmacol; 2002 Dec; 62(6):1464-70. PubMed ID: 12435815
[TBL] [Abstract][Full Text] [Related]
12. [(35)S]GTPĪ³S binding and opioid tolerance and efficacy in mouse spinal cord.
Madia PA; Navani DM; Yoburn BC
Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
Zernig G; Burke T; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
[TBL] [Abstract][Full Text] [Related]
14. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
Liu-Chen LY; Yang HH; Li S; Adams JU
J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
[TBL] [Abstract][Full Text] [Related]
15. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
16. Agonist-specific down regulation of mu-opioid receptors: Different cellular pathways are activated by different opioid agonists.
Binyaminy B; Gafni M; Shapira M; Sarne Y
Life Sci; 2008 Apr; 82(15-16):831-9. PubMed ID: 18358497
[TBL] [Abstract][Full Text] [Related]
17. Continuous intrathecal opioid treatment abolishes the regulatory effects of magnesium and guanine nucleotides on mu opioid receptor binding in rat spinal membranes.
Wong CS; Su YF; Watkins WD; Chang KJ
J Pharmacol Exp Ther; 1992 Jul; 262(1):317-26. PubMed ID: 1320689
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of mu and delta opiate receptors by morphine, selective agonists and antagonists and differentiating agents in SH-SY5Y human neuroblastoma cells.
Zadina JE; Harrison LM; Ge LJ; Kastin AJ; Chang SL
J Pharmacol Exp Ther; 1994 Sep; 270(3):1086-96. PubMed ID: 7932156
[TBL] [Abstract][Full Text] [Related]
19. Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats by reversing the coupling of mu-opioid receptors from Gs-protein to coupling to Gi-protein.
Tsai RY; Tai YH; Tzeng JI; Cherng CH; Yeh CC; Wong CS
Neuroscience; 2009 Dec; 164(2):435-43. PubMed ID: 19682558
[TBL] [Abstract][Full Text] [Related]
20. Functional reduction in mu-opioidergic system in the spinal cord under a neuropathic pain-like state following chronic ethanol consumption in the rat.
Narita M; Miyoshi K; Narita M; Suzuki T
Neuroscience; 2007 Feb; 144(3):777-82. PubMed ID: 17156932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
